Heart disease congenital
Not yet recruitingSafety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures
Safety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures
- Disease:Heart disease congenital
- Substances:Cangrelor Tetrasodium
Portugal- Participants:0–17 years
- Substances:Cangrelor Tetrasodium
- Sponsor:Chiesi Farmaceutici S.p.A.
















